Kedrion’s plasma-derived therapies help people suffering from debilitating conditions like Hemophilia and Immune Deficiencies.
The world of Kedrion Biopharma at a glance: discover the latest up-to-date news. All news. 20-11-2024 FDA Approves Kedrion's Bolognana Facility for Production of First and Only Treatment for PLGD-1, Ryplazim® Fort Lee, NJ, USA, November 19, 2024 /PRNewswire/ – Kedrion Biopharm...
Kedrion Biopharma 是一家国际生物制药公司,专门从事血浆衍生治疗产品的研发、生产和商业化,用于治疗和预防严重疾病、病症和病症,如纤溶酶原缺乏症、遗传性 X 因子缺乏症和血友病。其 38 种救命产品销往 100 多个国家。 参考来源:‘FDA Approves Kedrion's Bolognana Facility for Production of First and Only Trea...
Kedrion Biopharma has a long history of collaboration with the Italian National Health System, and partners the country in its move toward self-sufficiency in plasma-derived products. We bring this experience and the dedication to that goal to potential partners around the world. In recent years ...
FORT LEE, N.J.,Oct. 2, 2024/PRNewswire/ -- Following the agreement of binding terms signed inJuly 2024,Kedrion Biopharma Inc. and Biotest AG have now finalizedthe contractual terms ofthe long-term strategic agreement for the full commercialization and distrib...
CASTELVECCHIO PASCOLI,意大利,2023 年 12 月 7 日 /PRNewswire/ — 全球領先的 Kedrion Biopharma 開發、製造和商業化源自血漿的治療產品的生物製藥公司, 宣佈與Kamada Ltd.(納斯達克股票代碼:KMDA,TASE:KMDA:KMDA))簽署一份具有約束力的諒解備忘錄,該公司是一家以色列商業舞臺的全球生物製藥公司,也是特種等離子體...
patients that is transferred to those afflicted by the virus cannot be manufactured in millions of doses; its availability is limited by blood donations. The product being developed by Kamada Ltd and Kedrion Biopharma instead, aims to miniaturize the dosages so it can be produced in large ...
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as hemophilia, primar...
Melville-Based Kedrion Biopharma Scales Back Expansion PlansCallegari, John
“We are excited about our extended partnership with Kamada, a significant step in our commitment to hyperimmune therapies,” said Ugo Di Francesco, CEO of Kedrion Biopharma. “This collaboration emphasizes Kedri...